Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate of watch-and-wait patients was not inferior to that o ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

The patient was diagnosed with nongerminal-center B cell diffuse large B-cell lymphoma (DLBCL) 1 year after being diagnosed with primary biliary cholangitis (PBC).

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

The approval is for follicular-lymphoma patients whose cancer has a mutation called EZH2 and who either failed to respond to treatment or whose cancer has recurred after therapy. The mutation ...

About one in five people with lymphoma have follicular lymphoma ... your bone marrow but also can grow in your lymphatic system. Primary mediastinal large B-cell lymphoma This is a rare type ...